Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride-induced catalepsy in rats. |
| |
| Authors: | Jenny Ahlqvist Ruben Isacson Claes Wahlestedt Peter Salmi |
| |
| Institution: | 1. Department of Dermatology, Goztepe Research and Training Hospital, School of Medicine, Istanbul Medeniyet University, Istanbul, Turkey;2. Department of Dermatology, Southwest Hospital, The Third Military Medical University, Chongqing, P.R. China;3. Department of Dermatology and Venereology, Faculty of Medicine, Universitas Gadjah Mada/Dr. Sardjito Hospital, Jalan Farmako Sekip Utara, Yogyakarta, Indonesia;4. Department of Dermatology, Hamad Medical Corporation, Rumailah Hospital, Doha, Qatar;5. IZZ Immunologie-Zentrum Zürich, Walchestr. 11, CH 8006 Zurich, Switzerland;6. Department of Dermatology and Allergy, Technische Universität München, Munich, Germany;1. Therapeutic and Pharmaceutical Chemistry Laboratory, Pharmacy Department, Faculty of Medecine, University of Sidi Bel-Abbes, 22000, Algeria;2. Central Laboratory, University Hospital Center of Sidi Bel-Abbes, 22000, Algeria;3. Quality Control Laboratory, WanyLab, Algiers, 16002, Algeria |
| |
| Abstract: | The present study investigated potential anti-cataleptic properties of the prototype atypical antipsychotic clozapine and two newly developed atypical antipsychotics, olanzapine and quetiapine, which are structurally related and display similar pharmacological profiles to clozapine. Clozapine (2.5 mg kg(-1), s.c.), but not olanzapine (2.0 mg kg(-1), s.c.) and quetiapine (20.0 mg kg(-1), s.c.), blocked catalepsy induced either by the dopamine D(1/5) receptor antagonist SCH 23390 (50.0 microg kg(-1), s.c) or the selective dopamine D(2/3) receptor antagonist raclopride (4.0 mg kg(-1), s.c.). Such findings are consistent with the beneficial effects of clozapine in the management of drug-induced psychosis in parkinsonian patients, and suggest that neither olanzapine nor quetiapine may be a safe alternative to clozapine in this field. Furthermore, the results indicate that clozapine has a unique pharmacological profile that distinguishes it from olanzapine and quetiapine. The mechanisms underlying anti-cataleptic or anti-parkinsonian properties of clozapine are unclear but may be related to dopamine D(1) receptor agonism of clozapine. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
